HS
NGM

HighVista Strategies’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

HighVista Strategies’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-46,243
Closed -$705K – 120
2022
Q1 		$705K Buy
+46,243
New +$721K 0.45% 62

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

HighVista Strategies's NGM Position: Q2 2022 in Review

HighVista Strategies sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2022, closing a stake of 46,243 shares — an estimated $705K sold.

HighVista Strategies first reported a position in NGM in Q1 2022 and held it in 1 quarter. The position peaked at $705K in Q1 2022. 123 funds tracked by Wall St. Rank hold NGM as of Q2 2022.

  • HighVista Strategies reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • HighVista Strategies sold 46,243 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $705K.
  • HighVista Strategies first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • HighVista Strategies's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $705K in Q1 2022.
  • 123 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on HighVista Strategies's 13F filing for Q2 2022, filed 15 Aug 2022.